Australian Clinical Labs (ACL) Stock Overview
Provides pathology diagnostic services in Australia. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
ACL Community Fair Values
See what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Australian Clinical Labs Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$2.61 |
52 Week High | AU$3.86 |
52 Week Low | AU$2.47 |
Beta | 1.07 |
1 Month Change | -4.04% |
3 Month Change | -6.12% |
1 Year Change | -21.39% |
3 Year Change | -37.41% |
5 Year Change | n/a |
Change since IPO | -23.68% |
Recent News & Updates
Australian Clinical Labs Limited Just Missed Earnings - But Analysts Have Updated Their Models
Mar 02Recent updates
Australian Clinical Labs Limited Just Missed Earnings - But Analysts Have Updated Their Models
Mar 02Operational Improvements And New Genomic Tests Aim To Improve Future Outlook
Improving collection centers and digital transformations are set to enhance operational efficiency, boosting profit margins and supporting revenue growth.Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge
Sep 03Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?
Sep 02We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
Jun 20Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Feb 21Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
Dec 08Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
Aug 14Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)
Dec 22The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More
Dec 21The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Sep 01Shareholder Returns
ACL | AU Healthcare | AU Market | |
---|---|---|---|
7D | -3.7% | 3.0% | -0.3% |
1Y | -21.4% | -13.6% | 9.7% |
Return vs Industry: ACL underperformed the Australian Healthcare industry which returned -13.6% over the past year.
Return vs Market: ACL underperformed the Australian Market which returned 9.7% over the past year.
Price Volatility
ACL volatility | |
---|---|
ACL Average Weekly Movement | 4.6% |
Healthcare Industry Average Movement | 6.4% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 19.3% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: ACL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ACL's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 4,700 | Melinda McGrath | www.clinicallabs.com.au |
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients.
Australian Clinical Labs Limited Fundamentals Summary
ACL fundamental statistics | |
---|---|
Market cap | AU$507.56m |
Earnings (TTM) | AU$32.43m |
Revenue (TTM) | AU$741.27m |
Is ACL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACL income statement (TTM) | |
---|---|
Revenue | AU$741.27m |
Cost of Revenue | AU$470.41m |
Gross Profit | AU$270.86m |
Other Expenses | AU$238.43m |
Earnings | AU$32.43m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
Earnings per share (EPS) | 0.17 |
Gross Margin | 36.54% |
Net Profit Margin | 4.37% |
Debt/Equity Ratio | 24.4% |
How did ACL perform over the long term?
See historical performance and comparisonDividends
Does ACL pay a reliable dividends?
See ACL dividend history and benchmarksAustralian Clinical Labs dividend dates | |
---|---|
Ex Dividend Date | Sep 01 2025 |
Dividend Pay Date | Sep 23 2025 |
Days until Ex dividend | 3 days |
Days until Dividend pay date | 19 days |
Does ACL pay a reliable dividends?
See ACL dividend history and benchmarksCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/09/03 22:59 |
End of Day Share Price | 2025/09/03 00:00 |
Earnings | 2025/06/30 |
Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Australian Clinical Labs Limited is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Lyanne Harrison | BofA Global Research |
Citi Research | Citigroup Inc |
Mathieu Chevrier | Citigroup Inc |